Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.66 |
| ▸ | BACE1 | P56817 | 1/20 | 0.62 |
| ▸ | TLR2 | O60603 | 1/20 | 0.62 |
| ▸ | ERN1 | O75460 | 1/20 | 0.62 |
| ▸ | TLR1 | Q15399 | 1/20 | 0.62 |
| ▸ | TLR6 | Q9Y2C9 | 1/20 | 0.62 |
| ▸ | BCHE | P06276 | 2/20 | 0.59 |
| ▸ | TXNRD1 | Q16881 | 1/20 | 0.59 |
| ▸ | TXNRD3 | Q86VQ6 | 1/20 | 0.59 |
| ▸ | TXNRD2 | Q9NNW7 | 1/20 | 0.59 |
| ▸ | MAPT | P10636 | 5/20 | 0.58 |
| ▸ | APP | P05067 | 1/20 | 0.58 |
| ▸ | GAA | P10253 | 2/20 | 0.57 |
| ▸ | NFE2L2 | Q16236 | 3/20 | 0.56 |
| ▸ | TFEB | P19484 | 1/20 | 0.56 |
| ▸ | ABL1 | P00519 | 1/20 | 0.55 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.55 |
| ▸ | BCR | P11274 | 1/20 | 0.55 |
| ▸ | RAB9A | P51151 | 3/20 | 0.54 |
| ▸ | POLB | P06746 | 2/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3687130 | 1.00 | KDM4E (0.66) | KDM4EBACE1TLR2ERN1TLR1 | |
| SCHEMBL11260283 | 0.87 | KDM4E (0.73) | KDM4EBACE1TLR2ERN1TLR1 | |
| SCHEMBL11260285 | 0.87 | KDM4E (0.73) | KDM4EBACE1TLR2ERN1TLR1 | |
| SCHEMBL7724020 | 0.85 | BACE1 (0.82) | KDM4EBACE1TLR2ERN1TLR1 | |
| SCHEMBL7724027 | 0.85 | BACE1 (0.82) | KDM4EBACE1TLR2ERN1TLR1 | |
| SCHEMBL9689786 | 0.85 | KDM4E (0.68) | KDM4EBCHEMAPTGAANFE2L2 | |
| SCHEMBL21317661 | 0.85 | PKM (0.56) | KDM4EBACE1MAPTAPPGAA | |
| SCHEMBL16831490 | 0.85 | KDM4E (0.68) | KDM4EBCHEMAPTGAANFE2L2 | |
| SCHEMBL5084154 | 0.84 | MAPT (0.78) | BACE1BCHEMAPTRAB9ASMN1; SMN2 | |
| SCHEMBL5084150 | 0.84 | MAPT (0.78) | BACE1BCHEMAPTRAB9ASMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2025081932-A1 | RETINOL DERIVATIVE OR SALT THEREOF, AS WELL AS PREPARATION METHOD THEREFOR AND USE THEREOF | 深圳市护家科技有限公司 | 2025-04-24 | — | — | WO | claimed |
| CN-119841755-A | Retinol derivative or its salt, and preparation method and application thereof | 深圳市护家科技有限公司 | 2025-04-18 | — | — | CN | claimed |
| WO-2025081932-A1 | RETINOL DERIVATIVE OR SALT THEREOF, AS WELL AS PREPARATION METHOD THEREFOR AND USE THEREOF | 深圳市护家科技有限公司 | 2025-04-24 | — | — | WO | disclosed |
| CN-119841755-A | Retinol derivative or its salt, and preparation method and application thereof | 深圳市护家科技有限公司 | 2025-04-18 | — | — | CN | disclosed |
| US-7795310-B2 | Methods and reagents for the treatment of metabolic disorders | COMBINATORX, INC. (US) | 2010-09-14 | — | — | US | disclosed |
| EP-1781303-A4 | METHODS AND REAGENTS FOR THE TREATMENT OF METABOLIC DISORDERS | COMBINATORX INC (US) | 2008-07-02 | — | — | EP | disclosed |
| EP-1781303-A1 | METHODS AND REAGENTS FOR THE TREATMENT OF METABOLIC DISORDERS | CombinatoRx, Incorporated (US) | 2007-05-09 | — | — | EP | disclosed |
| US-20060069161-A1 | Methods and reagents for the treatment of metabolic disorders | COMBINATORX, INC. (US) | 2006-03-30 | — | — | US | disclosed |
| WO-2006004803-A1 | METHODS AND REAGENTS FOR THE TREATMENT OF METABOLIC DISORDERS | COMBINATORX, INCORPORATED (US) | 2006-01-12 | — | — | WO | disclosed |
| US-4981773-A | Method for stabilization of organic base substances against light | FUJI PHOTO FILM CO., LTD. (JP) | 1991-01-01 | — | — | US | disclosed |
| US-4026896-A | ANTIALLERGENS | KISSEI YAKUHIN KOGYO KABUSHIKI KAISHA (KISSEI PHARMACEUTICAL CO. LTD.) (JA) | 1977-05-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060069161-A1 | Methods and reagents for the treatment of metabolic disorders | LIPC, PNLIP, GOT2 | KDM4E 3045/4885BACE1 3331/4885TLR2 4268/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.